ST-segment Elevation as an AF Endophenotype

Completed · Not applicable

Conditions studied: Atrial Fibrillation

In brief

The purpose of this study is to look for a similarity in people's genes that may help understand which people could benefit from certain drugs for the treatment of atrial fibrillation (AF).

Key facts

Study ID

NCT01205529

Run by

Vanderbilt University Medical Center

People needed

161

Starts

2010-11-01

Expected to finish

2015-06-01

Last updated by the study team

2018-05-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18 years of age or older
• Undergoing AF ablation at Vanderbilt or MGH

You may not qualify if…

• Patients taking membrane active anti-arrhythmic drugs with sodium channel blocking properties (amiodarone, dronedarone, flecainide, propafenone) at the time of the ablation
• Patients with a history of Brugada syndrome or type 1 Brugada ECG pattern on the baseline ECG
• Patients with a history of drug-induced torsades de pointes
• Patients with a known history of hypersensitivity to procainamide, procaine or related drugs
• Patients with a history of systemic lupus erythematosus and myasthenia gravis
• Patients with a history of second degree AV block (Mobitz type II) or third degree AV block
• Women of child-bearing potential unless post-menopausal, surgically sterile, or have a negative pregnancy test day on the day of procedure
• Patients with dual chamber pacemakers or implantable defibrillators requiring ventricular pacing (uninterpretable ECG)
• Patients unable to give informed consent

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.